4 research outputs found
The Effects of a Multi-Flavonoid Supplement on Vascular and Hemodynamic Parameters in Older Pre-Hypertensives
Antioxidants have been shown to increase vasodilation, increasing vascular distensibility and decreasing blood pressure (BP) in individuals with elevated BP; therefore an additive effect would be expected when combined with exercise. The purpose of this study was to investigate the potential additive effects of an acute aerobic exercise bout paired with two weeks of anti-oxidant supplementation on post-exercise BP in middle-aged pre-hypertensives. Methods: 18 middle-aged subjects were randomly assigned to either the supplement or the placebo group in double-blinded fashion. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), Augmentation Index (AIx), central and peripheral pulse wave velocity (cPWV and pPWV, respectively) were assessed pre- and post-exercise prior to and following 2 weeks of supplementation in a double-blind design. Results: Following two weeks of supplementation, there was a significant decrease in SBP (132.2 ± 5.4 pre-supplementation to 124.9 ± 5.4 post-, p < 0.05) and MAP (100.2 ± 2.2 pre-supplementation to 94.6 ± 4.4 post-, p < 0.05). No significant differences were shown in DBP, AIx, cPWV, or pPWV. Conclusion: Two weeks of multi-flavonoid supplementation elicited a significant decrease in SBP and MAP in the treatment group with no changes in vascular parameters
Reduction of plasma aldosterone and arterial stiffness in obese pre- and stage1 hypertensive subjects after aerobic exercise
Obesity-related hypertension is associated with increased activity of the renin-angiotensin-aldosterone system (RAAS), increasing arterial stiffness. Aerobic exercise decreases pulse wave velocity (PWV), therefore a treatment option for hypertension and obesity. Assess RAAS activity and PWV before and after 4 weeks of aerobic training in unmedicated, pre-to-stage-1 hypertensives. Ten obese subjects (52±3.2 years, body mass index ¼ 33.5±1.4) performed 30 min of aerobic exercise on a treadmill 3 days per week at 65%of peak oxygen consumption (VO2peak). Descriptive characteristics, systolic and diastolic blood pressure (SBP and DBP), PWV, and a blood draw was performed at baseline, following the 4-week control and training interventions. No differences in descriptive characteristics during the control period were observed, however, a signi?cant decrease in plasma aldosterone (ALDO) (255.4±75 to 215.8±66 pg ml 1, P ¼ 0.001), SBP (140±12 to 136±10.4 mm Hg; P ¼ 0.02), DBP (89±4.2 to 85±6.3 mm Hg; P ¼ 0.03) and central PWV (11.2±0.6 to 9.8±0.8 m s 1; P ¼ 0.04) was shown pre-to-post exercise training. Four weeks of moderate-intensity aerobic training in obese, hypertensives decreases plasma ALDO independently of body weight and is signi?cantly correlated to decreases in PWV reductions
Risk of COVID-19 after natural infection or vaccinationResearch in context
Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health
Recommended from our members
Risk of COVID-19 after natural infection or vaccinationResearch in context
Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health